SCHEMBL4886065

SCHEMBL4886065

CC1CCN(C(=O)Oc2noc3ncccc23)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.54
ALDH1A1 P00352 4/20 0.54
MEN1 O00255 3/20 0.54
NPSR1 Q6W5P4 2/20 0.54
CYP1A2 P05177 1/20 0.54
CYP3A4 P08684 1/20 0.54
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54
GAA P10253 1/20 0.49
CTSB P07858 1/20 0.40
KDM4E B2RXH2 4/20 0.39
HSD17B10 Q99714 3/20 0.39
HPGD P15428 2/20 0.39
TSHR P16473 1/20 0.39
LIPE Q05469 1/20 0.39
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
MAPT P10636 1/20 0.38
TP53 P04637 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4704034 0.84 KMT2A (0.41) KMT2AALDH1A1MEN1NPSR1CYP1A2
SCHEMBL4705335 0.81 GAA (0.46) KMT2AALDH1A1MEN1NPSR1CYP1A2
SCHEMBL4704006 0.81 GAA (0.45) KMT2AALDH1A1MEN1NPSR1CYP1A2
SCHEMBL4885142 0.77 ALDH1A1 (0.54) KMT2AALDH1A1MEN1NPSR1CYP1A2
SCHEMBL1573909 0.77 KMT2A (0.54) KMT2AALDH1A1MEN1NPSR1CYP1A2
SCHEMBL4887653 0.74 ALDH1A1 (0.57) KMT2AALDH1A1MEN1NPSR1CYP1A2
SCHEMBL1573600 0.70 RAB9A (0.58) KMT2AALDH1A1MEN1NPSR1CYP1A2
SCHEMBL1573876 0.70 GAA (0.56) KMT2AALDH1A1MEN1NPSR1CYP1A2
SCHEMBL4882411 0.70 GAA (0.56) KMT2AALDH1A1MEN1NPSR1CYP1A2
SCHEMBL10040471 0.69 GAA (0.69) KMT2AALDH1A1MEN1NPSR1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8921404-B2 Azole derivatives in the form of lipase and phospholipase inhibitors SANOFI (FR) 2014-12-30 US disclosed
US-20080090867-A1 Antidiabetic agents; compounds have insulin-like effect; optionally ring C4-7 aza-substituted 3-substituted benzisoxazoles or benzisothiazoles; 1-(2-Methylbenzyl)-3-(5-nitrobenzo[d]isothiazol-3-yl)urea for example SANOFI-AVENTIS (FR) 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090867-A1 Antidiabetic agents; compounds have insulin-like effect; optionally ring C4-7 aza-substituted 3-substituted benzisoxazoles or benzisothiazoles; 1-(2-Methylbenzyl)-3-(5-nitrobenzo[d]isothiazol-3-yl)urea for example FABP4, GPR119, LIPE KMT2A 2135/4885ALDH1A1 647/4885MEN1 4408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.